Jeremy Force
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (3)
Purpose: Activating mutations in AKT genes are rare but play an important role in the commonly dysregulated PI3K/AKT/mTOR signaling pathway in multiple cancers. NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolled patients to targeted therapies based on matching tumor genomic alterations. Subprotocol Z1K evaluated ipatasertib, a pan-AKT inhibitor, in patients with AKT1 E17K -mutant metastatic tumors. Patients and Methods: Patients received ipatasertib 400 mg orally once daily in a 28-day cycle until progression or unacceptable toxicity. Patients with well-controlled diabetes were eligible. Patients with known KRAS , NRAS , HRAS , or BRAF mutations were excluded. Prior PI3K and mTOR inhibitors were allowed. Prior AKT inhibitors were excluded. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival, 6-month progression-free survival, and toxicity. Results: Thirty-five patients were enrolled, and 29 patients were included in the prespecified primary efficacy analysis. Multiple histologies were enrolled, with breast ( n = 18) and gynecologic ( n = 7) being the most common. The majority had >3 lines of prior therapy (19/29; 65.5%). The ORR was 24.1% (7/29; 90% confidence interval, 11.9%–40.6%) with P n = 25), nausea ( n = 13), and hyperglycemia ( n = 9). Grade 3/4 toxicities observed were consistent with reported toxicities for AKT inhibition. Twelve grade 3 events occurred that were thought to be at least possibly related to treatment. Conclusions: The study met its primary endpoint with an ORR of 24.1% ( P AKT1 E17K mutations. See related commentary by Dahmer Tiecher and Schram, p. 4863
Year:
2025
Year:
2023
Year:
2021
Collaborators (6)
Lawrence Rubinstein
Statistician
National Cancer Institute
Alice Chen
Head, Early Clinical Trial Development Program
National Cancer Institute
Lisa McShane
Associate Director, Division of Cancer Treatment & Diagnosis
National Cancer Institute
Robert Gray
Dana-Farber Cancer Institute
Kevin Kalinsky
Emory University
Carlos L. Arteaga
University of Texas Southwestern Medical Center
Make your next move.
Prepare your application
Review drafts before you send them.